GE Healthcare

GE Healthcare of Chalfont St. Giles, UK, is set to dedicate $1 billion of its total R&D budget over the next five years to expanding its advanced cancer diagnostic and molecular imaging capabilities as well as its technologies for biopharmaceuticals manufacturing and for cancer research. Announced alongside a $100 million open innovation challenge in New York, the billion-dollar investment crosses all lines of GE Healthcare’s global business and will enable the company to bring the most promising cancer ideas to market. The company’s solutions combine medical imaging, molecular diagnostics and health care information technology.